Giant Biogene

Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash

246 Views16 May 2024 18:55
Giant Biogene (2367 HK) aims to raise up to US$205m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through our ECM framework.
What is covered in the Full Insight:
  • Giant Biogene's recent performance
  • Analysts' take on the stock
  • The company's FY23 results
  • Deal terms
  • Concluding thoughts
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
(Paid Plans Only)